Brief: 4D Molecular Therapeutics Inc says Pursuant To Prospectus Supplement Relating To Offering, Co May Sell Up To $250.0 Million Of Common Stock
07/06/2024 22:39
June 7 (Reuters) - 4D Molecular Therapeutics Inc
FDMT.O :
* 4D MOLECULAR THERAPEUTICS INC - PURSUANT TO PROSPECTUS
SUPPLEMENT RELATING TO OFFERING, CO MAY SELL UP TO $250.0
MILLION OF COMMON STOCK
* 4D MOLECULAR THERAPEUTICS INC - ENTERED INTO A SALES
AGREEMENT
WITH LEERINK PARTNERS LLC
Further company coverage: FDMT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on 4D Molecular Therapeutics
See all news4D Molecular Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
4D Molecular Therapeutics Q2 net loss widens
Brief: 4D Molecular Therapeutics Q2 Net Income USD -72.936 Million Vs. IBES Estimate USD -70.3 Million
4D Molecular Therapeutics Inc expected to post a loss of $1.02 a share - Earnings Preview
Brief: 4d Molecular Therapeutics Says 4D-150 Continues To Be Well Tolerated With No New Safety Findings